Contraline Announces Acceptance of Abstracts to be Presented at 2023 American Urology Association and European Association of Urology Annual Meetings
Retrieved on:
Wednesday, April 26, 2023
Health, Other Health, General Health, Clinical Trials, Research, Science, Biotechnology, No-scalpel vasectomy, Abstract, Male, Reproductive medicine, MBBS, ADAM, AUA, Birth, Clinical trial, Vasectomy, American Urological Association, Doctor of Philosophy, Royal Melbourne Hospital, Epworth HealthCare, MD, Patient, Azoospermia, European Association of Urology, Safety, EAU, Birth control, Pharmaceutical industry, FRACS, Urology
The abstracts were written and submitted by investigators leading the study, and were accepted for presentation at the two largest, annual international urology meetings, the European Association of Urology (EAU) and the American Urological Association (AUA).
Key Points:
- The abstracts were written and submitted by investigators leading the study, and were accepted for presentation at the two largest, annual international urology meetings, the European Association of Urology (EAU) and the American Urological Association (AUA).
- The podium presentations by Nathan Lawrentschuk at AUA and Paul Anderson at EAU highlight the early research findings on the ADAM System.
- Contraline, Inc. is a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective contraception.
- The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia.